vs
查尔斯河实验室（CRL）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
查尔斯河实验室的季度营收约是登士柏西诺德的1.0倍（$994.2M vs $961.0M），登士柏西诺德净利率更高（-15.2% vs -27.8%，领先12.6%），登士柏西诺德同比增速更快（6.2% vs -0.8%），登士柏西诺德自由现金流更多（$60.0M vs $58.6M），过去两年登士柏西诺德的营收复合增速更高（0.4% vs -0.9%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
CRL vs XRAY — 直观对比
营收规模更大
CRL
是对方的1.0倍
$961.0M
营收增速更快
XRAY
高出7.0%
-0.8%
净利率更高
XRAY
高出12.6%
-27.8%
自由现金流更多
XRAY
多$1.4M
$58.6M
两年增速更快
XRAY
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $961.0M |
| 净利润 | $-276.6M | $-146.0M |
| 毛利率 | — | 46.1% |
| 营业利润率 | -28.5% | -14.5% |
| 净利率 | -27.8% | -15.2% |
| 营收同比 | -0.8% | 6.2% |
| 净利润同比 | -28.9% | 66.0% |
| 每股收益（稀释后） | $-5.57 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLXRAY
| Q4 25 | $994.2M | $961.0M | ||
| Q3 25 | $1.0B | $904.0M | ||
| Q2 25 | $1.0B | $936.0M | ||
| Q1 25 | $984.2M | $879.0M | ||
| Q4 24 | $1.0B | $905.0M | ||
| Q3 24 | $1.0B | $951.0M | ||
| Q2 24 | $1.0B | $984.0M | ||
| Q1 24 | $1.0B | $953.0M |
净利润CRLXRAY
| Q4 25 | $-276.6M | $-146.0M | ||
| Q3 25 | $54.4M | $-427.0M | ||
| Q2 25 | $52.3M | $-45.0M | ||
| Q1 25 | $25.5M | $20.0M | ||
| Q4 24 | $-214.5M | $-430.0M | ||
| Q3 24 | $69.7M | $-494.0M | ||
| Q2 24 | $94.1M | $-4.0M | ||
| Q1 24 | $73.0M | $18.0M |
毛利率CRLXRAY
| Q4 25 | — | 46.1% | ||
| Q3 25 | — | 48.8% | ||
| Q2 25 | — | 52.4% | ||
| Q1 25 | — | 53.0% | ||
| Q4 24 | — | 49.3% | ||
| Q3 24 | 34.6% | 52.1% | ||
| Q2 24 | 34.5% | 51.9% | ||
| Q1 24 | 34.1% | 53.1% |
营业利润率CRLXRAY
| Q4 25 | -28.5% | -14.5% | ||
| Q3 25 | 13.3% | -24.1% | ||
| Q2 25 | 9.7% | -13.7% | ||
| Q1 25 | 7.6% | 7.2% | ||
| Q4 24 | -16.7% | -56.2% | ||
| Q3 24 | 11.6% | -48.6% | ||
| Q2 24 | 14.8% | 5.1% | ||
| Q1 24 | 12.5% | 4.4% |
净利率CRLXRAY
| Q4 25 | -27.8% | -15.2% | ||
| Q3 25 | 5.4% | -47.2% | ||
| Q2 25 | 5.1% | -4.8% | ||
| Q1 25 | 2.6% | 2.3% | ||
| Q4 24 | -21.4% | -47.5% | ||
| Q3 24 | 6.9% | -51.9% | ||
| Q2 24 | 9.2% | -0.4% | ||
| Q1 24 | 7.2% | 1.9% |
每股收益（稀释后）CRLXRAY
| Q4 25 | $-5.57 | $-0.74 | ||
| Q3 25 | $1.10 | $-2.14 | ||
| Q2 25 | $1.06 | $-0.22 | ||
| Q1 25 | $0.50 | $0.10 | ||
| Q4 24 | $-4.17 | $-2.09 | ||
| Q3 24 | $1.33 | $-2.46 | ||
| Q2 24 | $1.74 | $-0.02 | ||
| Q1 24 | $1.30 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | $326.0M |
| 总债务越低越好 | $2.1B | $2.3B |
| 股东权益账面价值 | $3.2B | $1.3B |
| 总资产 | $7.1B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.68× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资CRLXRAY
| Q4 25 | $213.8M | $326.0M | ||
| Q3 25 | $207.1M | $363.0M | ||
| Q2 25 | $182.8M | $359.0M | ||
| Q1 25 | $229.4M | $398.0M | ||
| Q4 24 | $194.6M | $272.0M | ||
| Q3 24 | $210.2M | $296.0M | ||
| Q2 24 | $179.2M | $279.0M | ||
| Q1 24 | $327.0M | $291.0M |
总债务CRLXRAY
| Q4 25 | $2.1B | $2.3B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | $1.7B | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
股东权益CRLXRAY
| Q4 25 | $3.2B | $1.3B | ||
| Q3 25 | $3.4B | $1.5B | ||
| Q2 25 | $3.4B | $2.0B | ||
| Q1 25 | $3.2B | $2.0B | ||
| Q4 24 | $3.5B | $1.9B | ||
| Q3 24 | $3.8B | $2.5B | ||
| Q2 24 | $3.7B | $3.1B | ||
| Q1 24 | $3.6B | $3.3B |
总资产CRLXRAY
| Q4 25 | $7.1B | $5.4B | ||
| Q3 25 | $7.5B | $5.7B | ||
| Q2 25 | $7.6B | $6.1B | ||
| Q1 25 | $7.6B | $6.0B | ||
| Q4 24 | $7.5B | $5.8B | ||
| Q3 24 | $8.0B | $6.6B | ||
| Q2 24 | $7.9B | $6.9B | ||
| Q1 24 | $8.2B | $7.1B |
负债/权益比CRLXRAY
| Q4 25 | 0.68× | 1.70× | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | 0.90× | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $60.0M |
| 自由现金流率自由现金流/营收 | 5.9% | 6.2% |
| 资本支出强度资本支出/营收 | 8.9% | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $518.5M | $104.0M |
8季度趋势，按日历期对齐
经营现金流CRLXRAY
| Q4 25 | $147.5M | $101.0M | ||
| Q3 25 | $213.8M | $79.0M | ||
| Q2 25 | $204.6M | $48.0M | ||
| Q1 25 | $171.7M | $7.0M | ||
| Q4 24 | $159.4M | $87.0M | ||
| Q3 24 | $251.8M | $141.0M | ||
| Q2 24 | $193.5M | $208.0M | ||
| Q1 24 | $129.9M | $25.0M |
自由现金流CRLXRAY
| Q4 25 | $58.6M | $60.0M | ||
| Q3 25 | $178.2M | $40.0M | ||
| Q2 25 | $169.3M | $16.0M | ||
| Q1 25 | $112.4M | $-12.0M | ||
| Q4 24 | $83.7M | $36.0M | ||
| Q3 24 | $213.1M | $98.0M | ||
| Q2 24 | $154.0M | $156.0M | ||
| Q1 24 | $50.7M | $-9.0M |
自由现金流率CRLXRAY
| Q4 25 | 5.9% | 6.2% | ||
| Q3 25 | 17.7% | 4.4% | ||
| Q2 25 | 16.4% | 1.7% | ||
| Q1 25 | 11.4% | -1.4% | ||
| Q4 24 | 8.4% | 4.0% | ||
| Q3 24 | 21.1% | 10.3% | ||
| Q2 24 | 15.0% | 15.9% | ||
| Q1 24 | 5.0% | -0.9% |
资本支出强度CRLXRAY
| Q4 25 | 8.9% | 4.3% | ||
| Q3 25 | 3.5% | 4.3% | ||
| Q2 25 | 3.4% | 3.4% | ||
| Q1 25 | 6.0% | 2.2% | ||
| Q4 24 | 7.5% | 5.6% | ||
| Q3 24 | 3.8% | 4.5% | ||
| Q2 24 | 3.8% | 5.3% | ||
| Q1 24 | 7.8% | 3.6% |
现金转化率CRLXRAY
| Q4 25 | — | — | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | 0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
